Treatment of hypernephroma with xenogeneic immune RNA.
The treatment of patients with hypernephroma with xenogeneic immune RNA was discussed. The toxicity from xenogeneic immune RNA therapy was minimal in patients receiving simple doses from 4 to 64 mg intracutaneously and with cumulative doses of 450 mg during a 30-month period.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007109:Immunity; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology; D012313:RNA / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity
D012313:RNA